Christopher Rovaldi
Chief Operating Officer chez KEROS THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Christopher Rovaldi est SVP-Program Management & Operations chez Acceleron Pharma, Inc. M. Rovaldi a précédemment occupé le poste de directeur de la gestion des projets chez Idenix Pharmaceuticals LLC, d'associé de recherche principal chez Periodontix, Inc. et de directeur de la gestion des projets chez Cubist Pharmaceuticals LLC. Il a obtenu un diplôme d'études supérieures et un diplôme de premier cycle de l'Université du New Hampshire.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KEROS THERAPEUTICS, INC.
-.--% | 31/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Christopher Rovaldi
| Sociétés | Poste | Début |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Operating Officer | 01/02/2022 |
NS Pharma, Inc.
 NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | President | 01/05/2019 |
Anciens postes connus de Christopher Rovaldi
| Sociétés | Poste | Fin |
|---|---|---|
| ACCELERON PHARMA INC. | Chief Operating Officer | 01/05/2018 |
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2007 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01/01/2004 |
Periodontix, Inc.
 Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Corporate Officer/Principal | - |
Formation de Christopher Rovaldi
| University of New Hampshire | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KEROS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Periodontix, Inc.
Periodontix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ACI Global Corp., Periodontix, Inc. is a biopharmaceutical company that specializes in researching and developing next-generation antimicrobial agents for the prevention and treatment of periodontal disease. The private company is based in Watertown, MA. Periodontix was acquired by Demegen, Inc. on July 16, 2001 for $8.02 million. | Commercial Services |
NS Pharma, Inc.
NS Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Nippon Shinyaku Co., Ltd., NS Pharma, Inc. operates as a biopharmaceutical company. The private company is based in Paramus, NJ. | Health Technology |
